secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001564590-22-029405
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024
--------------------------------------------------------------------

- BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.
- Net loss $13.3M ($0.31/shr) vs net gain $1.7M ($0.06/shr) in Q2 2021.
- Cash $118.7M at June 30, 2022; projected runway into Q1 2024.
- FDA accepted sNDA for BREXAFEMME in recurrent VVC; PDUFA date Nov 30, 2022.
- Total prescriptions up 29% QoQ to ~5,141; >2,200 HCPs prescribed in Q2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/0001564590-22-029405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/scyx-8k_20220815.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-029405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer